A modular, evidence-grounded framework for rescuing, re-engineering, and accelerating biopharma assets Key Takeaways Blind Spots of Brute Force: Asset redevelopment significantly compresses clinical timelines but capturing this economic premium requires integrating heterogeneous biological, chemical, and clinical evidence into decision-ready evidence packages that conventional empirical screening cannot efficiently produce at scale. TechBio Differentiation: While generic AI